• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Sensei Biotherapeutics Inc.

    3/4/26 3:52:51 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNSE alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox checkedNoneEntity Type
    0001829802
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Sensei Biotherapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Sensei Biotherapeutics, Inc.
    Street Address 1Street Address 2
     1405 RESEARCH BLVD, SUITE 125
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     ROCKVILLE
     MARYLAND
     
     20850
     (240) 243-8000 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Gerry
    Christopher
    Street Address 1Street Address 2
     c/o Sensei Biotherapeutics, Inc. 
     1405 RESEARCH BLVD, SUITE 125
    CityState/Province/CountryZIP/Postal Code
     ROCKVILLE
     MARYLAND
     20850
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Craver
    Josiah
    Street Address 1Street Address 2
     c/o Sensei Biotherapeutics, Inc. 
     1405 RESEARCH BLVD, SUITE 125
    CityState/Province/CountryZIP/Postal Code
     ROCKVILLE
     MARYLAND
     20850
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Ricks
    Tom
    Street Address 1Street Address 2
     c/o Sensei Biotherapeutics, Inc. 
     1405 RESEARCH BLVD, SUITE 125
    CityState/Province/CountryZIP/Postal Code
     ROCKVILLE
     MARYLAND
     20850
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Parikh
    Anand
    Kiran
    Street Address 1Street Address 2
     c/o Sensei Biotherapeutics, Inc. 
     1405 RESEARCH BLVD, SUITE 125
    CityState/Province/CountryZIP/Postal Code
     ROCKVILLE
     MARYLAND
     20850
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Donenberg
    Phillip
    B.
    Street Address 1Street Address 2
     c/o Sensei Biotherapeutics, Inc. 
     1405 RESEARCH BLVD, SUITE 125
    CityState/Province/CountryZIP/Postal Code
     ROCKVILLE
     MARYLAND
     20850
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Holmen
    Bob
    Street Address 1Street Address 2
     c/o Sensei Biotherapeutics, Inc. 
     1405 RESEARCH BLVD, SUITE 125
    CityState/Province/CountryZIP/Postal Code
     ROCKVILLE
     MARYLAND
     20850
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Humer
    Kristian
    Street Address 1Street Address 2
     c/o Sensei Biotherapeutics, Inc. 
     1405 RESEARCH BLVD, SUITE 125
    CityState/Province/CountryZIP/Postal Code
     ROCKVILLE
     MARYLAND
     20850
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-02-17
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox not checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button checked Yes Radio button not checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     Leerink Partners
     39011
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    53 State Street, 40th Floor
     
    City State/Province/CountryZIP/Postal Code
     Boston
     MASSACHUSETTS
     02109
    State(s) of SolicitationCheckbox checkedAll StatesCheckbox not checkedForeign/Non-US
     




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    348906500
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    348906500
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
      
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    104
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    11700003
    USDCheckbox not checkedEstimate
    Finders' Fees$
    100000
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Sensei Biotherapeutics, Inc./s/ Christopher GerryChristopher GerryPresident and Principal Executive Officer2026-03-04




    Get the next $SNSE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNSE

    DatePrice TargetRatingAnalyst
    6/2/2025$5.00Buy
    H.C. Wainwright
    5/14/2024$5.00Overweight
    Stephens
    3/10/2022$12.00 → $10.00Overweight
    Piper Sandler
    7/1/2021$12.00Buy → Hold
    Berenberg
    6/29/2021$30.00 → $14.00Outperform → Perform
    Oppenheimer
    6/29/2021Outperform → Perform
    Oppenheimer
    More analyst ratings

    $SNSE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Sensei Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $5.00

    6/2/25 8:54:54 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens initiated coverage on Sensei Biotherapeutics with a new price target

    Stephens initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $5.00

    5/14/24 8:02:37 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler reiterated coverage on Sensei Biotherapeutics with a new price target

    Piper Sandler reiterated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $10.00 from $12.00 previously

    3/10/22 10:13:48 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    SEC Filings

    View All

    SEC Form D filed by Sensei Biotherapeutics Inc.

    D - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    3/4/26 3:52:51 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    2/18/26 8:45:53 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Sensei Biotherapeutics Inc.

    8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)

    2/13/26 5:29:45 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on February 19, 2026, Sensei's Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 shares of the Company's common stock in connection with their employment, including a grant to Anand Parikh of an option to purchase 1,239,305 shares of the Company's common stock in connection with his employment as Chief Operating Officer of the Company (collectively, the "Option Awards"). The Option Awards were granted as an inducement material to the individuals entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Awards have an exercise price of $2

    2/25/26 6:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

    Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ET Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The

    2/18/26 8:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Egle Therapeutics Appoints John Celebi as Chief Executive Officer

    PARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in patients with autoimmune diseases and cancer, today announced the appointment of John Celebi, M.B.A., as chief executive officer. Mr. Celebi is a seasoned biotechnology executive with over 30 years of experience building and scaling innovative life sciences companies and has been a member of the Egle board of directors since 2024. Mr. Celebi's appointment comes as Egle enhances its clinical development focus on autoimmune diseases, where recent validation of the IL-2 mechanism h

    1/7/26 8:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Parikh Anand Kiran

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    2/19/26 9:45:04 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Parikh Anand Kiran

    3 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    2/19/26 9:44:11 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Donenberg Phillip B.

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    2/17/26 5:01:24 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Leadership Updates

    Live Leadership Updates

    View All

    Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro

    11/14/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    - Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month

    8/6/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    - Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide

    5/9/24 7:30:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Financials

    Live finance-specific insights

    View All

    Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

    Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational all-oral, multi-node inhibitor of the PI3K/AKT/mTOR pathway in development across solid tumor settings, including endometrial and breast cancer Sensei to host an audio-only conference call and webcast today, February 18, 2026, at 8:30 a.m. ET Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The

    2/18/26 8:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Adopts Stockholder Rights Agreement

    BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i

    3/7/23 5:15:00 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sensei Biotherapeutics Reports Third Quarter 2021 Results and Recent Business Highlights

    - SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - VISTA science symposium to be webcast Tuesday, November 16 at 4:00 p.m. ET – - Ended third quarter 2021 with cash, cash equivalents and marketable securities of 156.7 million; company reiterated cash runway at least into first half 2024 BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next

    11/9/21 8:54:48 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SNSE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

    SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    3/7/24 6:00:48 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Sensei Biotherapeutics Inc. (Amendment)

    SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    2/13/24 5:34:37 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Sensei Biotherapeutics Inc.

    SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)

    11/3/23 5:03:47 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care